The aim of this study was to determine whether standard treatments for Tobacco Dependence affect smokinginduced changes in intrasynaptic dopamine (DA) concentration. Forty-three otherwise healthy adult cigarette smokers (10 to 40 cigarettes per day) were treated with either practical group counseling (PGC) psychotherapy (n = 14), bupropion HCl (n = 14), or matching pill placebo (n = 15) (random assignment) for 8 weeks. Before and after treatment, each subject underwent a bolus-plus-continuous-infusion 11 C-raclopride positron emission tomography (PET) scanning session, during which he or she smoked a regular cigarette. The PET scanning outcome measure of interest was percent change in smoking-induced 11 C-raclopride binding potential (BP ND ) in the ventral caudate/nucleus accumbens (VCD/NAc), as an indirect measure of DA release. Although the entire study sample had a smaller mean smoking-induced reduction in VCD/NAc BP ND after treatment (compared to before treatment), this change was highly correlated with smaller total cigarette puff volumes (and not other treatment variables). These data indicate that smoking-induced DA release is dosedependent, and is not significantly affected by reductions in daily smoking levels or treatment type.
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Introduction
Recent studies using the radiotracer 11 C-raclopride and positron emission tomography (PET) have demonstrated (indirectly) that cigarette smoking (Brody et al., 2004 (Brody et al., , 2006 Scott et al., 2007) and nicotine intake (Takahashi et al., 2008) increase intrasynaptic dopamine (DA) concentration in the ventral striatum/nucleus accumbens (VST/ NAc) in human smokers (though not all studies using these and similar methods have shown this effect (Tsukada et al., 2002; Barrett et al., 2004; Montgomery et al., 2007) ). In these studies, DA release has been associated with the craving-reducing (Brody et al., 2004 (Brody et al., , 2006 and pleasurable (Barrett et al., 2004; Brody et al., 2009 ) effects of smoking, as well as the severity of nicotine dependence (Scott et al., 2007) . Nicotineinduced DA release has also been demonstrated in studies of nonhuman primates using similar methodology (Dewey et al., 1999; Tsukada et al., 2002; Marenco et al., 2004) and in rodents using microdialysis (Di Chiara and Imperato, 1988; Damsma et al., 1989; Pontieri et al.,1996; Sziraki et al., 2001) . Despite these findings that point to the importance of striatal DA release in response to cigarette smoking, the effects of treatment for Tobacco Dependence (TD) on smokinginduced DA release have not been reported.
Currently, there are several effective first-line treatments for TD, including (but not limited to) the medication bupropion HCl (Zyban) and the psychotherapy 'practical group counseling' (PGC) (Marlatt and Gordon, 1985; Carmody, 1990; Fiore et al., 2000; Hall et al., 2002; Gold et al., 2002; Abrams et al., 2003; Holmes et al., 2004) . A standard (2-month) course of treatment with bupropion HCl (administered along with brief counseling) results in abstinence rates of roughly 40% (Hurt et al., 1997) , with longer term (12-month) abstinence rates of about 20 to 30% (Jorenby et al., 1999; Simon et al., 2004; Paluck et al., 2006) . Abstinence rates with medication alone are typically lower than those achieved with the combination of medication plus psychotherapy (Hall et al., 2002) . Similar to medication administered alone, PGC typically results in abstinence rates of about 40% after 2 months and 20% after 6 months of treatment (Fiore et al.,1994) , with a recent literature review concluding that group psychotherapies have roughly twice the abstinence rates of control conditions (Stead and Lancaster, 2005) .
